RCT: Safety and efficacy of a third dose of the Pfizer Covid-19 vaccine during the Delta wave.
24 Mar, 2022 | 09:46h | UTCSafety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine – New England Journal of Medicine
Commentary on Twitter
A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with two doses. #COVID19 #IDTwitter https://t.co/IeHOgVhU8a pic.twitter.com/wValXSdyHX
— NEJM (@NEJM) March 23, 2022